Showing results (301-310 of 314) with videos related to

Sort By:
Pageof 32
Vaccine|March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of ageTheresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science (New York, N.Y.)|June 9, 2012
Massive phytoplankton blooms under Arctic sea iceKevin R Arrigo, Donald K Perovich, Robert S Pickart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Cancer Treatment Reviews|December 5, 2017
Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup ConsortiumS C Clement, L C M Kremer, F A Verburg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 32